Headlines

Roche’s bispecific antibody treatment for blood cancer nabs first approval in Canada

A T-cell engaging bispecific antibody developed by Roche has got its first green light in Canada for the treatment of relapsed or refractory forms of the blood cancer diffuse large B-cell lymphoma (DLBCL).

CytomX stock falls by 10% as AbbVie abandons ADC collaboration

The US biotech CytomX has lost a collaboration partner as AbbVie pulled out of a collaboration developing an antibody-drug conjugate (ADC) for the treatment of solid tumours.

Content provided by Thermo Fisher Scientific - Biosciences

Is GMP grade good enough? What mRNA manufacturers need to know when buying raw materials

Starting with the end in mind when choosing mRNA raw materials help mitigate costly risks. Seeking quality attributes that go beyond GMP grade is key.

Pharmaron’s Liverpool based gene therapy CDMO wins UK government grant

Pharmaron Beijing Co Ltd says its Liverpool, UK based gene therapy CDMO has obtained a grant from the UK government’s life sciences innovation manufacturing fund (LSMIF) to expand its facilities.

Lonza's facility in Visp, Switzerland © Lonza

Lonza’s new drug product manufacturing line in Switzerland goes live

Swiss CDMO Lonza has increased capacity and capabilities at its Visp, Switzerland site, with the completion of a new line for cGMP clinical and commercial drug product manufacturing.